Immunomodulatory Effects of Low Dose cis-Diaminedichloroplatinum (Cisplatin) Combined with UFT and PSK in Patients with Advanced Colorectal Cancer

REFERENCES

• Greene W.C., Leonard W.J., Depper J.M., Nelson D.L. The Human Interleukin-2 Receptor: Normal and Abnormal Expression in T Cells and in Leukemias Induced the Human T-Lymphotropic Retroviruses. Am. Int. Med. 1988; 105: 560–568
   Web of Science ®Google Scholar
• Hakin A.A. Peripheral Blood Lymphocytes from Patients with Cancer Lack Interleukin-2 Receptor Expression: Isolation of mRNA Encoding IL-2R. Cancer Detect. Prev. 1988; 12: 59–66
   PubMedGoogle Scholar
• Holter W., Golman C.K., Casabo L., Nelson D.L. Expression of Functional IL-2 Receptor by Lipopolysaccharide and Interferon γ Stimulated Human Monocytes. J. Immunol. 1987; 138: 2917–2930
   PubMed Web of Science ®Google Scholar
• Smith K.A. The Interleukin-2 Receptor. Annu. Rev. Cell Biol. 1989; 5: 671–678
   Google Scholar
• Rubin L.A., Kurrman C.C., Fritz M.E., Biddison W.E., Boutin B., Yarchoan R., Nelson D.L. Soluble Interleukin-2 Receptors are Released from Activated Human Lymphoid Cells In Vitro. J. Immunol. 1985; 135: 3172–3178
   PubMed Web of Science ®Google Scholar
• Nelson D.L., Rubin L.A., Kurrman C.C., Fritz M.E., Boutin B. An Analysis of the Cellular Requirements for the Production of Soluble Interleukin-2 Receptors In Vitro. J. Clin. Immunol. 1986; 6: 114–118
   PubMed Web of Science ®Google Scholar
• Oliff A. The Role of Tumor Necrosis Factor (Cachectin) in Cachexia. Cell 1988; 54: 141–142
   PubMed Web of Science ®Google Scholar
• Beutler B., Greenwalt D., Humes J.D., Chang M., Pan Y-C.E., Mathison J., Ulevitch R., Cerami A. Identity of Tumor Necrosis Factor and the Macrophage-Secreted Factor Cachectin. Nature 1986; 316: 552–554
   Web of Science ®Google Scholar
• Cerami A., Ikeda Y., Le Trang N., Hotez P.J., Beutler B. Weight Loss Associated with an Endotoxin-Induced Mediator from Peritoneal Macrophages: the Role of Cachectin (Tumor Necrosis Factor). Immunol. Lett. 1985; 11: 173–177
   PubMed Web of Science ®Google Scholar
• Tartaglia L.A., Goeddel D.V. Two TNF Receptors. Immunol. Today 1992; 56: 151–153
   Google Scholar
• Engelmann H.-P., Novick D., Wallach D. Tumor Necrosis Factor-Binding Proteins Purified from Human Urine. Evidence for Immunological Cross-Reactivity with Cell Surface Tumor Necrosis Factor Receptors. J. Biol. Chem. 1990; 265: 1531–1536
   PubMed Web of Science ®Google Scholar
• Engelmann H., Holtmann H., Brakebusch C., Avni Y.S., Sarov I., Nophar Y., Hadas E., Leitner O., Wallach D. Antibodies to a Soluble Form of a Tumor Necrosis Factor (TNF) Receptor Have TNF-like Activity. J. Biol. Chem. 1990; 265: 14497–14504
   PubMed Web of Science ®Google Scholar
• Nophar Y., Kemper O., Brakebusch C., Engelmann H., Zwang R., Aderka D., Holtmann H., Wallach D. Soluble Forms of Tumor Necrosis Factor Receptors (Tnf-Rs).The cDNA for the Type I TNF-R, Cloned Using Amino Acid Sequence Data of its Soluble Form, Encodes Both the Cell Surface and a Soluble Form of the Receptor. EMBO J. 1990; 9: 3269–3278
   PubMed Web of Science ®Google Scholar
• Porteu F., Nathan C. Shedding of Tumor Necrosis Factor Receptors by Activated Human Neutrophils. J. Exp. Med. 1990; 172: 599–607
   PubMed Web of Science ®Google Scholar
• Lantz M., Gullberg U., Nilsson E., Olsson I. Characterization In Vitro of a Human Tumor Necrosis Factor Binding Protein: A Soluble Form of a Tumor Necrosis Factor Receptor. J. Clin. Invest. 1990; 86: 1396–1402
   PubMed Web of Science ®Google Scholar
• Van Ostade X., Vandenabeele P., Everaerdt B., Loetscher H., Gentz R., Brockhaus M., Lesslauer W., Tavernier J., Brockaert P., Fiers W. Human TNF Mutants with Selective Activity on the P55 Receptor. Nature 1993; 361: 266–269
   PubMed Web of Science ®Google Scholar
• Hahn T., Toker L., Budilovsky S., Aderka D., Eshhar Z., Wallach D. Use of a Monoclonal Antibodies of a Human Cytotoxin for Its Isolation and for Examining the Self-Induction of Resistance to this Protein. Proc. Natl. Acad. Sci. USA 1985; 82: 3814–3818
   PubMed Web of Science ®Google Scholar
• Nophar Y., Holtmann H., Ber R., Wallach D. Dominance of Resistance to the Cytocidal Effect of Tumor Necrosis Factor in Heterokaryons Formed by Fusion of Resistant and Sensitive Cells. J. Immunol. 1988; 140: 3456–3460
   PubMed Web of Science ®Google Scholar
• Wallach D., Holtmann H., Engelmann H., Nophar Y. Sensitization and Desensitization to Lethal Effects of Tumor Necrosis Factor and of Interleukin-1. J. Immunol. 1988; 140: 2994–2999
   PubMed Web of Science ®Google Scholar
• Shibata M., Takekawa M., Amano S. Increased Serum Concentrations of Soluble Tumor Necrosis Factor Receptor I in Noncachectic and Cachectic Patients with Advanced Gastric and Colorectal Cancer. Surg. Today 1998; 28: 884–888
   PubMed Web of Science ®Google Scholar
• Shibata M., Takekawa M. Increased Serum Concentration of Circulating Soluble Receptor for Interleukin-2 and Its Effect as a Prognostic Indicator in Cachectic Patients with Gastric and Colorectal Cancer. Oncology 1999; 56: 54–58
   PubMed Web of Science ®Google Scholar
• Fiorentino D.F., Bond M.W., Mosmann T.R. Two Types of Mouse Helper T Cells: Th2 Secretes a Factor that Inhibits Cytokine Production by Th1 Clones. J. Exp. Med. 1989; 170: 2081–2086
   PubMed Web of Science ®Google Scholar
• Mosmann T.R., Coffman R.L. Th1 and Th2 Cells: Different Patterns of Lymphokine Secretion Lead to Different Functional Properties. Annu. Rev. Immunol. 1989; 7: 145–173
   PubMed Web of Science ®Google Scholar
• Jeneway C.A., Jr., Carding S., Jones B. CD4+ T Cells: Specificity and Function. Immunol. Rev. 1988; 101: 39–80
   PubMed Web of Science ®Google Scholar
• Powrie F., Coffman R.L. Cytokine Regulation of T-Cell Function: Potential for Therapeutic Intervention. Immunol. Today 1993; 14: 270–272
   PubMedGoogle Scholar
• Howard M., O'Garra A., Ishida H., DeWaal Malefyt R., DeVries J. Biologic Properties of Interleukin-10. J. Clin. Immunol. 1992; 12: 239–247
   PubMed Web of Science ®Google Scholar
• Taga K., Mostowski H., Tosato G. Human Interleukin-10 Can Directly Inhibit T-Cell Growth. Blood 1993; 81: 2964–2971
   PubMed Web of Science ®Google Scholar
• De Waal Malefyt R., Abrams J., Bennet B. Interleukin-10 (IL-10) Inhibits Cytokine Synthesis by Human Monocytes: An Autoregulatory Role of IL-10 Produced by Monocytes. J. Exp. Med. 1991; 174: 1209–1220
   PubMed Web of Science ®Google Scholar
• Bartik M.M., Takesue B.Y., Mokyr M.B. Melphalan-Induced Enhancement of Antitumor Immune Reactivity in Thymocytes of Adult BALB/C Mice Bearing a Large MOPC-315 Tumor. Cancer Res. 1987; 47: 4848–4896
   PubMed Web of Science ®Google Scholar
• Mathe G., Halle-Pennenko O., Bourut C. Effectiveness of Murine Leukemia Chemotherapy According to the Immune State. Cancer Immunol. Immunother. 1977; 2: 139
   Web of Science ®Google Scholar
• Nagarkatti M., Toney D.M., Nagarkatti P.S. Immunomodulation by Various Nitrosoureas and Its Effect on the Murine Host Bearing a Syngeneic Tumor. Cancer Res. 1989; 49: 6587–6599
   PubMed Web of Science ®Google Scholar
• Turk J.L., Parker D. Effect of Cyclophosphamide on Immunological Control Mechanisms. Immunol. Rev. 1982; 65: 99–105
   PubMed Web of Science ®Google Scholar
• Xy Z.-Y., Hosokawa M., Morikawa K., Hatakeyama M., Kobayashi H. Overcoming Suppression of Antitumor Immune Reactivity in Tumor-Bearing Rats by Treatment with Bleomycin. Cancer Res. 1988; 48: 6658–6670
   PubMed Web of Science ®Google Scholar
• Kleinerman E.S., Zwelling L.A., Muchmore A.V. Enhancement of Naturally Occurring Human Spontaneous Monocyte-Mediated Cytotoxicity by cis-Diaminedichloroplatinum (II). Cancer Res. 1980; 40: 3099–3105
   PubMed Web of Science ®Google Scholar
• Lichtenstein A.K., Pende D. Enhancement of Natural Killer Cytotoxicity by cis-Diaminedichloroplatinum (II) In Vivo and In Vitro. Cancer Res. 1986; 46: 639–648
   PubMed Web of Science ®Google Scholar
• Margolin K., Doroshow J., Akman S., Leong L.A., Morgan R.J. Treatment of Advanced Melanoma with Cisplatin and Alpha Interferon. Proc. Am. Assoc. Clin. Oncol. 1990; 7: 277
   Google Scholar
• Richner J., Cerny T., Joss R.A., Raschko J., Somlo G. Phase II Study of Continuous IFN α2b Combined with CDDP in Advanced Malignant Melanoma. Proc. Am. Assoc. Clin. Oncol. 1990; 9: 280
   Google Scholar
• Silverman P., Creager R.J., Spitzer T.R., Sniechinski I., Goldberg D. A Phase II Trial of Cisplatin and Interferon-Alpha-2B in Advanced Malignant Melanoma, Breast Carcinoma, And Non-Small Cell Lung Carcinoma. Proc. Am. Assoc. Clin. Oncol. 1991; 10: 297
   Google Scholar
• Ehrke M.J., Mihich E., Berd D., Mastrangelo M.J. Effects of Anticancer Drugs on the Immune System in Humans. Semin. Oncol. 1989; 16: 230–237
   PubMed Web of Science ®Google Scholar
• Mitchell M.S. Combining Chemotherapy with Biological Response Modifiers in the Treatment of Cancer. J. Natl. Cancer Inst. 1988; 80: 1445–1451
   PubMed Web of Science ®Google Scholar
• Torisu M., Hayashi Y., Ishimitsu T., Fujimura T., Iwasaki K., Katano M., Yamamoto H., Kimura Y., Takasue M., Kondo M., Nomoto K. Significant Prolongation of Disease-Free Period Gained by Oral Polysaccharide K (PSK) Administration after Curative Surgical Operation of Colorectal Cancer. Cancer Immunol. Immunother. 1990; 31: 261–268
   PubMed Web of Science ®Google Scholar
• Nio Y., Shiraishi Y., Tsubono M., Morimoto H., Tseng C.C., Iwai S., Tobe T. In Vitro Immunomodulating Effect of Protein-Bound Polysaccharide PSK on Peripheral Blood, Regional Nodes, and Spleen Lymphocytes in Patients with Gastric Cancer. Cancer Immunol. Immunother. 1991; 32: 335–341
   PubMed Web of Science ®Google Scholar
• Kariya Y., Okamoto N., Fujimoto T., Inoue N., Kihara T., Sigie K., Yagita M., Kanzaki H., Mori T., Uchida A. Lysis of Fresh Human Tumor Cells by Autologous Peripheral Blood Lymphocytes and Tumor-Infiltrating Lymphocytes Activated by PSK. Jpn. J. Cancer Res. 1991; 82: 1044–1050
   PubMedGoogle Scholar
• Vanky F., Wang P., Klein E. The Polysaccharide K (PSK) Potentiates In Vitro Activation of the Cytotoxic Function in Human Blood Lymphocytes by Autologous Tumor Cells. Cancer Immonol. Immunother. 1992; 35: 193–198
   PubMed Web of Science ®Google Scholar
• Hirai R., Oguchi Y., Sugita N., Matsunaga K., Nomoto K. Enhancement of T-cell Proliferation by PSK. Int. J. Immunopharmacol. 1993; 15: 745–750
   PubMed Web of Science ®Google Scholar
• Yunoki S., Tanaka N., Hizuta A., Orita K. Enhancement of Antitumor Cytotoxicity of Hepatic Lymphocytes by Oral Administrations of PSK. Int. J. Immunopharmacol. 1994; 16: 123–130
   PubMed Web of Science ®Google Scholar
• Nakazato H., Koike A., Saji S., Ogawa N., Sakamoto J. Efficacy of Immunochemotherapy as Adjuvant Treatment after Curative Resection of Gastric Cancer. Lancet 1994; 343: 1122–1123
   PubMed Web of Science ®Google Scholar
• Bass H.Z., Yamashita N., Clememt T.L. Heterogeneous Mechanisms of Human Cytotoxic T Lymphocyte Generation I. Differential Helper T Cell Requirement for the Generation of Cytotoxic Effector Cells from Cd8(+) Precursor Subpopulations. J. Immunol. 1992; 149: 2489–2495
   PubMed Web of Science ®Google Scholar
• Banchereau J. Converging and Diverging Properties of Human Interleukin-4 and Interleukin-10. Behring. Inst. Mitt. 1995; 96: 58–68
   PubMedGoogle Scholar
• Pellegrini P., Berghella A.M., Del Beato T., Cicia S., Adorno D., Casciani C.U. Disregulation in TH1 and TH2 Subsets of Cd4(+) T Cells in Peripheral Blood of Colorectal Cancer Patients and Involvement in Cancer Establishment and Progression. Cancer Immunol. Immunother. 1996; 42: 1–14
   PubMed Web of Science ®Google Scholar
• Chen Q., Daniel V., Maher D.W., Hersey P. Production of IL-10 by Melanoma Cells: Examination of Its Role in Immunosuppression Mediated by Melanoma. Int. J. Cancer 1994; 56: 755–760
   PubMed Web of Science ®Google Scholar
• Figueria L., Zuber M., Merlo A. Cytokine Gene Transcription in Renal Cell Carcinoma. Br. J. Surg. 1993; 80: 1322–1325
   PubMed Web of Science ®Google Scholar
• Gastl G.A., Abrams J.S., Nanus D.M., Oosterkamp R., Silver J., Liu F., Chen M., Albino A.P., Bander N.H. Interleukin-10 Production by Human Carcinoma Cell Lines and Its Relationship to Interleukin-6 Expression. Int. J. Cancer 1993; 55: 96–101
   PubMed Web of Science ®Google Scholar
• Pisa P., Halapi E., Pisa E.K. Selective Expression of Interleukin-10, Interferon Gamma, and Granulocyte-Macrophage Colony Stimulation Factor in Ovarian Cancer Biopsies. Proc. Natl. Acad. Sci. USA 1992; 89: 7708–7712
   PubMed Web of Science ®Google Scholar
• Smith D.R., Kunkel S.L., Burdick M.D. Production of Interleukin-10 by Human Bronchogenic Carcinoma. Am. J. Pathol. 1994; 145: 18–25
   PubMedGoogle Scholar
• Gianotti L., Fortis C., Braga M., Gentilini O., Vignali A., Dicarlo V. Radical Oncologic Surgery Affects the Circulatory Levels of Interleukin-10. J. Surg. Oncol. 1997; 66: 244–247
   PubMed Web of Science ®Google Scholar
• Kucharnik T., Winde J.G., Domschke W., Stoll R. Colon Carcinoma Cell Lines Stimulate Monocytes and Lamina Propria Mononuclear Cells to Produce IL-10. Clin. Exp. Immunol. 1997; 110: 296–302
   PubMed Web of Science ®Google Scholar
• Loercher A.E., Nash M.A., Kavanagh J.J., Plastsoucas C.D., Freedman R.S. Identification of an IL-10-Producing HLA-DR-Negative Monocyte Subset in the Malignant Ascites of Patients with Ovarian Carcinoma That Inhibits Cytokine Protein Expression and Proliferation of Autologous T Cells. J. Immunol. 1999; 163: 6251–6260
   PubMed Web of Science ®Google Scholar